[go: up one dir, main page]

EP1646353A4 - Fusion proteins for the treatment of cns - Google Patents

Fusion proteins for the treatment of cns

Info

Publication number
EP1646353A4
EP1646353A4 EP04776038A EP04776038A EP1646353A4 EP 1646353 A4 EP1646353 A4 EP 1646353A4 EP 04776038 A EP04776038 A EP 04776038A EP 04776038 A EP04776038 A EP 04776038A EP 1646353 A4 EP1646353 A4 EP 1646353A4
Authority
EP
European Patent Office
Prior art keywords
cns
treatment
fusion proteins
fusion
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP04776038A
Other languages
German (de)
French (fr)
Other versions
EP1646353A2 (en
Inventor
Elliott A Gruskin
Anthony O Caggiano
Jennifer Iaci
Michael P Zimber
Gargi Roy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acorda Therapeutics Inc
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Priority to EP17164945.2A priority Critical patent/EP3210999B1/en
Priority to ES17164945T priority patent/ES2831031T3/en
Priority to EP10184697.0A priority patent/EP2354155B1/en
Publication of EP1646353A2 publication Critical patent/EP1646353A2/en
Publication of EP1646353A4 publication Critical patent/EP1646353A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP04776038A 2003-05-16 2004-05-17 Fusion proteins for the treatment of cns Ceased EP1646353A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP17164945.2A EP3210999B1 (en) 2003-05-16 2004-05-17 Fusion proteins for treatment of cns
ES17164945T ES2831031T3 (en) 2003-05-16 2004-05-17 Fusion proteins for CNS treatment
EP10184697.0A EP2354155B1 (en) 2003-05-16 2004-05-17 Fusion Proteins for Treatment of CNS

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47123603P 2003-05-16 2003-05-16
US47130003P 2003-05-16 2003-05-16
US47124003P 2003-05-16 2003-05-16
US47123903P 2003-05-16 2003-05-16
US47437203P 2003-05-29 2003-05-29
PCT/US2004/015661 WO2004110359A2 (en) 2003-05-16 2004-05-17 Fusion proteins for the treatment of cns

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP10184697.0A Division EP2354155B1 (en) 2003-05-16 2004-05-17 Fusion Proteins for Treatment of CNS
EP17164945.2A Division EP3210999B1 (en) 2003-05-16 2004-05-17 Fusion proteins for treatment of cns

Publications (2)

Publication Number Publication Date
EP1646353A2 EP1646353A2 (en) 2006-04-19
EP1646353A4 true EP1646353A4 (en) 2008-06-04

Family

ID=33556640

Family Applications (3)

Application Number Title Priority Date Filing Date
EP04776038A Ceased EP1646353A4 (en) 2003-05-16 2004-05-17 Fusion proteins for the treatment of cns
EP17164945.2A Expired - Lifetime EP3210999B1 (en) 2003-05-16 2004-05-17 Fusion proteins for treatment of cns
EP10184697.0A Expired - Lifetime EP2354155B1 (en) 2003-05-16 2004-05-17 Fusion Proteins for Treatment of CNS

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP17164945.2A Expired - Lifetime EP3210999B1 (en) 2003-05-16 2004-05-17 Fusion proteins for treatment of cns
EP10184697.0A Expired - Lifetime EP2354155B1 (en) 2003-05-16 2004-05-17 Fusion Proteins for Treatment of CNS

Country Status (7)

Country Link
EP (3) EP1646353A4 (en)
JP (5) JP5399612B2 (en)
AU (1) AU2004247025B8 (en)
CA (1) CA2525782C (en)
ES (1) ES2831031T3 (en)
MX (2) MX351062B (en)
WO (1) WO2004110359A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666852B2 (en) * 2002-04-22 2010-02-23 Agenta Biotechnologies, Inc. Wound and cutaneous injury healing with a nucleic acid encoding a proteoglycan polypeptide
AU2003304173A1 (en) 2002-05-04 2005-01-04 Acorda Therapeutics, Inc. Compositions and methods for promoting neuronal outgrowth
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
JP2007532094A (en) 2003-05-16 2007-11-15 アコーダ セラピューティクス、インク． Proteoglycan-degrading mutant for CNS treatment
MXPA06013345A (en) 2004-05-18 2008-10-31 Acorda Therapeutics Inc Methods of purifying chondroitinase and stable formulations thereof.
ES2393748T3 (en) 2005-09-26 2012-12-27 Acorda Therapeutics, Inc. Compositions and methods of using ABCI chondroitinase mutants
JP2009536821A (en) * 2006-05-12 2009-10-22 バハラ バイオテック インターナショナル リミテッド Novel thrombolytic molecules and methods for their production
JP5279491B2 (en) 2006-05-19 2013-09-04 愛知県 Brain damage improver
AU2007307736C1 (en) * 2006-10-10 2014-04-10 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
JP2010509612A (en) * 2006-11-14 2010-03-25 ジェネンテック インコーポレイテッド Activity regulator of neuronal regeneration
WO2008149428A1 (en) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. Therapeutic agent and preventive agent for autoimmune disease, inflammation and nerve disease
US8410050B2 (en) * 2008-02-29 2013-04-02 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
AU2015200220A1 (en) * 2008-02-29 2015-02-12 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
JP2013535507A (en) * 2010-08-13 2013-09-12 ジョージタウン ユニバーシティ GGF2 and methods of use
WO2013039244A1 (en) 2011-09-15 2013-03-21 生化学工業株式会社 Agent for promoting skeletal muscle regeneration
GB201322396D0 (en) 2013-12-18 2014-02-05 Univ Nottingham Transduction
TW201803893A (en) * 2016-06-28 2018-02-01 萬校之母－博洛尼亞大學 TAT[kappa]-CDKL5 fusion proteins, compositions, formulations, and use thereof
US11396529B2 (en) 2020-11-12 2022-07-26 National Sun Yat-Sen University Isolated peptide, anti-cancer medicinal composition including the same and method of specifically reducing or inhibiting activities of cancer cells using the same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062067A1 (en) * 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
WO2002055684A2 (en) * 2001-01-09 2002-07-18 Univ Iowa Res Found Synthetic proteins containing a protein transduction domain
WO2002083179A2 (en) * 2001-04-12 2002-10-24 Bioaxone Therapeutique Inc. Fusion proteins
WO2003100031A2 (en) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2004017044A2 (en) * 2002-08-15 2004-02-26 Acorda Therapeutics, Inc. Chimeric protein

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804604A (en) 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5674980A (en) 1989-12-21 1997-10-07 Biogen Inc Fusion protein comprising tat-derived transport moiety
CA2161125A1 (en) * 1993-04-23 1994-11-10 Michael Joseph Ryan Cloning and expression of the chondroitinase i and ii genes from p. vulgaris
WO1995013091A1 (en) * 1993-11-12 1995-05-18 International Technology Management Associates, Ltd. Methods of repairing connective tissues
JPH07316068A (en) * 1994-05-25 1995-12-05 Canji Inc Tumor suppressor-fused protein
GB9622500D0 (en) * 1996-10-29 1997-01-08 Oxford Biomedica Ltd Therapeutic gene
US20010006630A1 (en) * 1997-09-02 2001-07-05 Oron Yacoby-Zeevi Introducing a biological material into a patient
ES2313886T3 (en) * 1999-03-16 2009-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services NEW CHEMICAL PROTEIN FOR THE PREVENTION AND TREATMENT OF HIV INFECTION.
SE9901428D0 (en) * 1999-04-21 1999-04-21 Karolinska Innovations Ab Amphibodies
MEP3208A (en) * 1999-06-08 2010-02-10 Regeneron Pharma Modified chimeric polypeptides with improved pharmacokinetic properties
AU781600B2 (en) * 1999-12-02 2005-06-02 Biomarin Pharmaceutical Inc. Attenuation of fibroblast proliferation
IL160188A0 (en) * 2001-08-13 2004-07-25 Univ Florida Materials and methods to promote repair of nerve tissue
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
WO2000062067A1 (en) * 1999-02-28 2000-10-19 Washington University Novel transduction molecules and methods for using same
WO2002055684A2 (en) * 2001-01-09 2002-07-18 Univ Iowa Res Found Synthetic proteins containing a protein transduction domain
WO2002083179A2 (en) * 2001-04-12 2002-10-24 Bioaxone Therapeutique Inc. Fusion proteins
WO2003100031A2 (en) * 2002-05-20 2003-12-04 Board Of Regents, The University Of Texas System Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues
WO2004017044A2 (en) * 2002-08-15 2004-02-26 Acorda Therapeutics, Inc. Chimeric protein

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"ROUTE OF ADMINISTRATION - FDA", 11 January 2006 (2006-01-11), XP055243674 *
BRADBURY E J ET AL: "Chondroitinase ABC promotes functional recovery after spinal cord injury", NATURE, NATURE PUBLISHING GROUP, LONDON, GB, vol. 416, 11 April 2002 (2002-04-11), pages 636 - 640, XP002245003, ISSN: 0028-0836 *
FROM WIKIPEDIA: "Route of administration", 5 January 2016 (2016-01-05), XP055243671 *
MCGEE A W ET AL: "The Nogo-66 receptor: focusing myelin inhibition of axon regeneration", TRENDS IN NEUROSCIENCE, ELSEVIER, AMSTERDAM, NL, vol. 26, no. 4, April 2003 (2003-04-01), pages 193 - 198, XP004418152, ISSN: 0166-2236 *

Also Published As

Publication number Publication date
WO2004110359A2 (en) 2004-12-23
JP2013049677A (en) 2013-03-14
MXPA05012306A (en) 2006-04-18
EP2354155A3 (en) 2011-09-07
JP6141571B2 (en) 2017-07-12
EP2354155B1 (en) 2017-05-03
WO2004110359A3 (en) 2006-08-17
EP2354155A2 (en) 2011-08-10
CA2525782C (en) 2019-02-05
MX351062B (en) 2017-09-29
EP3210999B1 (en) 2020-08-26
ES2831031T3 (en) 2021-06-07
JP2020111578A (en) 2020-07-27
CA2525782A1 (en) 2004-12-23
EP1646353A2 (en) 2006-04-19
EP3210999A1 (en) 2017-08-30
AU2004247025B2 (en) 2011-06-23
JP2017125035A (en) 2017-07-20
JP6913428B2 (en) 2021-08-04
AU2004247025B8 (en) 2011-06-30
JP2007516229A (en) 2007-06-21
AU2004247025A1 (en) 2004-12-23
JP2014221793A (en) 2014-11-27
JP5656314B2 (en) 2015-01-21
JP5399612B2 (en) 2014-01-29
WO2004110359A9 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
IL262513A (en) Protein purification
IL166751A0 (en) Modified transferin-antibody fusion proteins
EP1688439A4 (en) Fused protein composition
IL173456A0 (en) Process for the preparation of 4-amino-3-quinolinecarbonitriles
IL176384A0 (en) Novel fused pyrrolocarbazoles
HK1096394A1 (en) Fused pyrrolocarbazoles and methods for the preparation thereof
EP1646353A4 (en) Fusion proteins for the treatment of cns
IL176326A0 (en) Process for the production of proteins
EP1549343A4 (en) Method for the treatment of nephritis using anti-pdgf-dd antibodies
IL175743A0 (en) Process for the preparation of thiazolopyrimidines
SI1656455T1 (en) Process for the purification of recombinant polypeptides
GB0200689D0 (en) Fusion proteins
HK1095145A1 (en) Process for the preparation of n-arylmorpholinones n-
PL371583A1 (en) Process for the preparation of 7alpha-methylsteroids
SG111997A1 (en) Improved process for the preparation of polyalkylphenoxyaminoalkanes
HK1087111A1 (en) Process for the preparation of nicotinaldehydes
IL164788A0 (en) Process for the preparation of 3-isochromanone
GB0311108D0 (en) Proteins
GB0522915D0 (en) Methods for recombinant immunoglobulin treatment
PL376745A1 (en) Process for the purification of tnf-binding proteins using imac
HU0300255D0 (en) Process for the preparation of 2-phenyl-4-methyl-1-tosil-piperazine
AU2003290331A8 (en) Protein purification means
SI1395580T1 (en) Method for the purification of triazolylmethylepoxides
GB0300503D0 (en) Proteins
GB0318686D0 (en) Proteins

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20051214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL HR LT LV MK

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C12P 21/06 20060101AFI20061005BHEP

RIN1 Information on inventor provided before grant (corrected)

Inventor name: GRUSKIN, ELLIOTT, A.

Inventor name: IACI, JENNIFER

Inventor name: ROY, GARGI

Inventor name: ZIMBER, MICHAEL, P.

Inventor name: CAGGIANO, ANTHONY, O.

A4 Supplementary search report drawn up and despatched

Effective date: 20080506

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 38/51 20060101ALI20080425BHEP

Ipc: C12N 9/88 20060101ALI20080425BHEP

Ipc: C12P 21/06 20060101AFI20061005BHEP

Ipc: C07K 14/475 20060101ALI20080425BHEP

17Q First examination report despatched

Effective date: 20080905

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20160923